ArticleMicroorganisms2025
Analysis of Gene Differences Between F and B Epidemic Lineages of Bandavirus Dabieense.
Article in Microorganisms, 2025. The graph could read no effect estimate from its abstract, so it casts no vote on the map. Cited by 5 papers.
What it found
Each row is one number read from the abstract, on the scale the paper reported it, with its interval. Left of the dashed line favours the treatment, right favours the comparator. Under each row is the sentence it came from. New to these charts? A ten-minute tutorial.
The abstract states no effect estimate the extractor could read, or names no intervention and outcome on the map, so this paper lights no cell and moves no belief. It is still indexed, cited and linked below.
The trial behind it
Trials whose registry record cites this paper, or whose number appears in the abstract. A trial that started after this paper was published is citing it as background, not reporting it.
Neither the registry nor the abstract names a trial number. If this is a trial report, that itself is worth knowing.
Who cites it
5 citing papers in PubMed.
- Phylogeographic epidemiology of Dabie bandavirus in East Asia: divergent transmission networks and genotype‑linked clinical severity.Infectious diseases of poverty · 2026Article
- Research progress on antiviral drugs and vaccines for severe fever with thrombocytopenia syndrome.Frontiers in immunology · 2026Review
- Review
- Advances in research on severe fever with thrombocytopenia syndrome virus.Frontiers in microbiology · 2025Review
- Dabie bandavirus identified from patients with severe fever with thrombocytopenia syndrome in northwestern of Hubei Province, China, 2024.Frontiers in public health · 2025Article
Corrections and comments
PubMed lists nothing against this paper. Absence here is not a guarantee, only a check that was made.
Authors and funding
7 authors.
Funding
Abstract
The prevalence of SFTS is becoming increasingly widespread and is expected to become a significant security issue. The article discusses the prevalence regions and genetic differences in two SFTSV lineages, so as to provide a scientific data basis for the clinical control and prevention of fever with thrombocytopenia syndrome. The literature involving SFTSV patients from 2009 to 2023 and SFTSV complete genome sequences uploaded by NCBI were collected and sorted out, based on time and SFTSV lineage division, we analyzed viral gene sequence. SFTSV patient data were continuously reported from 2009 to 2023, involving five countries including China, South Korea, Japan, Thailand, and Vietnam. There are obvious lineage and host divisions between the SFTSV lineages prevalent in China and abroad. The sources of B-lineage SFTSV samples are mainly concentrated in South Korea, Japan, and the middle and lower reaches of Hubei or Zhejiang in China, with half of the samples coming from humans and half from animals, and the F series SFTSV samples were mainly collected from provinces such as Anhui and Henan in China, with the main source being human patients. The F-lineage SFTSV is the highest proportion in the middle and upper provinces in China. The B lineage has recently appeared in Zhejiang and Taiwan and is prevalent abroad. Using prediction software based on molecular structure prediction technology, analyze the differences between the B and F lineages of SFTSV through prediction methods such as nucleotide mutations, gene recombination, mutation sites, and evolution rates. Conclusively, the differences in SFTSV between B and F lineages may be related to gene recombination of M and L fragments, it was also found that the B lineage had a lower recombination rate and mutation rate than the F lineage, and the evolutionary rate was prominently different. Comparative analysis of the differences in two SFTSV lineage genes could further understand the epidemic status of SFTSV and provide help and more insights for the prevention of the spread of specific types of SFTSV.
Indexed as
Identifiers
What OpenQuestion holds
Registered trials
Read under generation 80e0d062 · epoch 390. Bibliography from PubMed, PubMed Central and OpenAlex; grants from NIH RePORTER; trial links from ClinicalTrials.gov; estimates, votes and beliefs from the OpenQuestion graph.